ResMed Inc. (RMD) — Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is constructive — consensus is a manageable bar, gross margin is the primary swing factor, and the MatrixCare divestiture announcement adds a capital-return catalyst that could drive upside surprise on EPS.

Heading into fiscal Q4 2026, ResMed's consensus bar looks achievable: revenue consensus of ~$1.46B implies ~8% YoY growth, consistent with the high-single-digit constant-currency trajectory management has guided to all year, and non-GAAP EPS consensus of ~$2.89 sits modestly above the $2.86 reported in Q3. Gross margin is the key swing factor — management guided FY2026 gross margin to 62–63%, and Q3 came in at 62.8% (non-GAAP), so the Q4 print needs to hold or expand sequentially to validate the full-year range; any upside here (driven by component cost improvements and manufacturing efficiencies) would likely drive EPS above consensus. Management's tone has been consistently confident since the April 30 Q3 earnings call, with the June 2 William Blair conference disclosing that over $200M in share buybacks were executed in Q4 — well above the $175M minimum guided on the Q3 call — providing a meaningful EPS tailwind. The July 7 8-K announcing the $490M MatrixCare divestiture to Frazier Healthcare is the most significant post-earnings development, signaling accelerated capital return (ASR program) and a cleaner, higher-margin portfolio going into FY2027. The stock has recovered from its late-May/early-June lows (~$182) to ~$211 as of August 5, but still trades at ~18x NTM P/E versus a 10-year average near 40x, suggesting the multiple remains compressed and the stock has not fully priced in a beat. The key wildcard is RCS (Residential Care Software) revenue trajectory: management has guided to mid-to-high single-digit growth in the back half of FY2026, but Q3 came in at only +4% constant currency, and any further deceleration here could offset device/mask strength.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar on revenue and EPS. Gross margin is the bigger swing factor — any sequential expansion above Q3’s 62.8% non-GAAP would likely drive EPS upside, while masks & accessories growth (including VirtuOx contribution) is the top revenue swing factor.

Table 1 — Current Quarter Snapshot (4QFY2026, Quarter Ending June 30, 2026)

Source: Visible Alpha Consensus and Actuals Data; RMD Q3 FY2026 Earnings Release (April 30, 2026); RMD Q3 FY2026 Earnings Call Transcript.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Revenue & Non-GAAP EPS)

Pattern: RMD has beaten or matched revenue consensus in 7 of the last 8 quarters, and beaten non-GAAP EPS in 7 of 8 quarters, with EPS beats typically driven by gross margin outperformance. The one revenue miss (1QFY26) was marginal (-0.2%). The consistent beat pattern, combined with management’s above-minimum buyback execution in Q4, supports a constructive setup.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been stable since the April 30 Q3 earnings call, with no formal revisions. The most significant post-earnings development is the July 7 MatrixCare divestiture announcement, which signals a portfolio shift toward higher-margin SaaS and accelerated capital return — a positive tone shift heading into FY2027.

Source: RMD Q3 FY2026 Earnings Call Transcript (April 30, 2026); RMD 8-K (July 7, 2026); William Blair Growth Stock Conference Transcript (June 2, 2026).

5. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for 4QFY26 and FY2026 have been broadly stable since the Q3 print, with only marginal drift (-0.1% to -0.3%). FY2027 estimates have been revised down ~2% to reflect the MatrixCare divestiture removing ~$220M of revenue from the base. The narrow gap between consensus and guidance suggests limited cushion but also limited downside risk on the core business.

The FY2027 estimate revision is structural (MatrixCare divestiture), not a signal of organic deterioration. On an apples-to-apples basis excluding MatrixCare (~$220M revenue, ~$55M non-GAAP operating profit), the underlying FY2027 growth trajectory remains intact. The August 6 call will be the first opportunity for management to provide formal FY2027 guidance, which is the key catalyst for estimate re-rating.

Source: Visible Alpha Consensus and Actuals Data; RMD 8-K (July 7, 2026).

6. Stock Performance

Key Takeaway: RMD has underperformed both XLV and the S&P 500 since the April 30 Q3 earnings date, driven almost entirely by multiple compression (NTM P/E contracted from ~22x to ~18x over 12 months) rather than estimate cuts. The stock bottomed in early June (~$182) and has recovered ~23% to ~$211, but remains well below its 52-week high. The recovery has been driven by sentiment improvement (MatrixCare divestiture, buyback acceleration) rather than earnings revisions.

RMD vs. XLV (Healthcare ETF) vs. S&P 500 (SPY) — Indexed to 100 at April 30, 2026 (Q3 FY26 Earnings Date). Source: Yahoo Finance / Stock Price Data.

Key events since April 30, 2026 earnings: (1) May 29 — RMD dropped sharply from ~$208 to ~$190 (macro/sector rotation); (2) June 2 — William Blair Conference: CEO disclosed >$200M Q4 buybacks and Oura partnership, stock stabilized; (3) July 7 — MatrixCare divestiture 8-K: stock rallied from ~$195 to ~$220 on portfolio simplification and capital return signal; (4) July 8 — Pullback to ~$206 on broader market weakness; (5) August 4–5 — Recovery to ~$223 on strong healthcare sector earnings (LLY, ZBH beats). Over the full period, RMD returned approximately -1.3% vs. XLV +12.4% and SPY +7.1%, reflecting sector underperformance driven by multiple compression rather than fundamental deterioration.

Source: Yahoo Finance / Stock Price Data.

7. Material News & Developments

Key Takeaway: The MatrixCare divestiture is the most significant post-earnings development — it accelerates capital return, simplifies the portfolio, and removes a drag on RCS growth optics heading into FY2027. The Oura partnership and buyback acceleration are secondary positives.

• July 7, 2026 — MatrixCare Divestiture Announced (8-K): ResMed agreed to sell MatrixCare to Frazier Healthcare Partners for $490M cash. MatrixCare represented ~$220M of FY2026 revenue and ~$55M of non-GAAP operating profit. Proceeds to fund an accelerated share repurchase (ASR) program and general corporate purposes. Expected to close in 1QFY27. Implication: Removes the lowest-margin, slowest-growing RCS asset; simplifies the portfolio; ASR is a near-term EPS catalyst.
• June 2, 2026 — William Blair Growth Stock Conference: CEO Mick Farrell disclosed that RMD executed >$200M in share buybacks in Q4 FY26 (vs. $175M minimum guided), and guided FY2027 buybacks to >$800M for the year (>$200M/quarter). Also announced formal strategic alliance with Oura Ring, directing Oura members with elevated nighttime breathing disturbances into ResMed’s sleep care pathway. Implication: Buyback acceleration is a direct EPS tailwind; Oura partnership expands top-of-funnel demand generation.
• June 1, 2026 — Noctrix Health Acquisition Closed: $340M acquisition of Noctrix (FDA de novo device for Restless Leg Syndrome) closed as guided. Noctrix has ~$24M annual revenue run rate (higher growth than RMD), higher gross margins than RMD, and ~-$0.02 Q4 EPS dilution. Revenue reported in Americas Devices. Implication: Modest near-term dilution; longer-term platform for noninvasive nerve stimulation (RLS, PTSD, insomnia).
• May 19, 2026 — Oura Partnership Announced: Formal strategic alliance with Oura Ring enabling Oura members detecting elevated nighttime breathing disturbances to be directed into ResMed’s sleep health education and care pathway. Complements existing Apple Watch and Samsung Galaxy Watch integrations. Implication: Expands wearable-to-clinical funnel; supports GLP-1 demand generation narrative.
• August 5, 2026 — Eli Lilly Q2 2026 Earnings Beat: LLY reported adjusted EPS of $8.38 (vs. $6.01 consensus) and raised FY2026 revenue guidance to $85–87B. Mounjaro revenue of $9.9B and Zepbound of $4.93B both beat. LLY also launched a CVS Health partnership for GLP-1 access at $29 MinuteClinic visits. Implication (Positive Read-through for RMD): Continued GLP-1 demand strength validates RMD’s thesis that GLP-1 patients have ~10% higher CPAP start rates and higher resupply rates.
• August 3, 2026 — Inspire Medical Systems (INSP) Q2 2026 Earnings: INSP reported U.S. revenue decline driven by coding/reimbursement disruption (~$40M adverse impact in Q2; $120–130M full-year impact estimated). However, prior authorization submissions are improving and management characterized the disruption as temporary. Announced Project Horizon restructuring to generate $30M annualized savings. Implication (Mixed Read-through for RMD): INSP’s reimbursement headwinds are specific to hypoglossal nerve stimulation CPT codes and do not directly affect CPAP reimbursement. However, improving prior authorization trends and GLP-1 commentary (long-term benefit) are positive for the broader sleep apnea market.
• July 28, 2026 — Philips (PHG) Q2 2026 Earnings: PHG reported adjusted EBITA margin of 16.4% (vs. 11.9% consensus), aided by tariff refunds and strong medical scanner demand. Sleep & Respiratory Care delivered low single-digit growth, led by Europe and Japan. PHG guided full-year comparable sales growth of 3–4.5% and EBITA margin of 13.5–14% (including tariff refund). Implication (Direct Read-through for RMD): PHG’s sleep & respiratory segment growing in Europe/Japan is a positive demand signal for RMD’s international device and mask business. PHG’s tariff refund benefit and cost inflation commentary (high single-digit for FY2026) are relevant to RMD’s own cost structure.
• July 30, 2026 — Apnimed IPO: Apnimed (sleep apnea drug developer backed by Shionogi) raised $192M in its U.S. IPO, selling 12M shares at $16 each with strong demand (multiple times oversubscribed). Implication: Validates investor appetite for sleep apnea therapeutics; reinforces the market opportunity narrative that benefits RMD.
• July 31, 2026 — Novo Nordisk Ziltivekimab Trial Failure: NVO’s heart drug ziltivekimab failed to reduce major adverse cardiovascular events in the ZEUS trial; NVO stock fell ~8.5%. Implication (Neutral for RMD): Failure is in a non-GLP-1 asset; does not affect GLP-1 demand trajectory. NVO’s core GLP-1 business (Wegovy, Ozempic) remains intact.
• July 7, 2026 — CFO Transition Confirmed: Brett Sandercock retirement and Aaron Bloomer (formerly Exact Sciences CFO) succession confirmed. Bloomer to join ahead of the August 6 earnings call. Implication: Orderly transition; Bloomer’s background in high-growth healthcare SaaS is relevant to RMD’s RCS strategy.

8. Peer Commentaries / Read-Throughs (Last 60 Days)

Key Takeaway: The most actionable read-throughs come from PHG (direct: sleep & respiratory demand in Europe/Japan positive; tariff/cost inflation manageable) and INSP (direct: sleep apnea market disruption is reimbursement-specific to HNS, not CPAP; improving prior auth trends are a positive leading indicator). LLY’s GLP-1 beat reinforces RMD’s demand generation thesis.

Note on methodology: Only forward-looking commentary delivered after each peer’s most recent earnings report is included below. Retrospective commentary about prior-quarter results is excluded. All commentary pertains to the current reporting period (calendar Q2 2026 / RMD’s fiscal Q4 2026) or forward outlook.

PHG (Royal Philips) — Q2 2026 Earnings Call (July 28, 2026)

Read-through type: DIRECT (Sleep & Respiratory, Margins, Tariffs/Cost Inflation)

• Sleep & Respiratory Demand (Direct): PHG’s Sleep and Respiratory Care segment delivered “low single-digit growth” in Q2 2026, led by Europe and Japan. This is a direct positive read-through for RMD’s international device and mask business, confirming that the underlying demand environment for sleep and respiratory products in key international markets remains constructive. PHG’s international sleep growth is consistent with RMD’s Q3 guidance for high single-digit ROW masks growth.
• Procedure/Referral Trends (Indirect): PHG noted “healthy patient volumes, procedural growth, and sustained capital investment by larger health systems” in North America, and European health systems “investing in productivity, digitization, and modernizing care delivery.” This broad healthcare utilization strength is an indirect positive for RMD’s patient funnel.
• Margins — Cost Inflation (Direct): PHG guided to “high single-digit cost inflation for the full year 2026,” driven by component cost increases and “freight costs significantly increasing” due to Middle East tensions. PHG noted cost inflation will have a “greater impact in the second half, as higher costs held in inventory are recognized in the P&L.” This is a direct read-through for RMD’s own gross margin trajectory — RMD has flagged similar component and freight cost pressures, and PHG’s commentary suggests these headwinds may intensify in Q4 (RMD’s fiscal Q4 = calendar Q2). However, PHG also noted it “largely completed the US tariff refund process during the quarter, receiving virtually all of the tariff amount claimed” — suggesting tariff refunds may be a one-time benefit for peers but not a recurring tailwind.
• Tariff Refunds (Direct): PHG’s Q2 adjusted EBITA margin of 16.4% significantly exceeded the 11.9% consensus, aided by a US tariff refund benefit. PHG noted it “largely completed the US tariff refund process” in Q2. This is relevant for RMD: if RMD has similarly pursued tariff refunds, there could be a one-time margin benefit in Q4 FY26. However, RMD has not publicly disclosed a tariff refund program, so this is speculative.
• Forward Guidance (Indirect): PHG reiterated full-year comparable sales growth of 3–4.5% and underlying EBITA margin of 12.5–13% (13.5–14% including tariff refund). PHG expects Q3 margins to be “below prior year” due to higher cost inflation and unfavorable mix, with a “meaningful step up” in Q4. This back-end loaded margin profile is consistent with RMD’s own trajectory (Q3 non-GAAP gross margin of 62.8% already near the top of the 62–63% FY guidance range).

INSP (Inspire Medical Systems) — Q2 2026 Earnings Call (August 3, 2026)

Read-through type: DIRECT (Sleep Apnea Market Demand, Reimbursement, GLP-1 Commentary)

• Sleep Apnea Demand Recovery (Direct): INSP noted “improved trends in key data points, such as prior authorization submissions” and stated that centers are “getting comfortable with the coding” and returning to utilization levels. INSP characterized the coding/reimbursement disruption as “temporary” and expects the adverse impact to “decrease sequentially as we move into the third and fourth quarters.” This is a direct positive read-through for RMD: improving sleep apnea procedure volumes and prior authorization trends suggest the broader sleep apnea market is recovering from the reimbursement disruption, which should benefit CPAP demand as well.
• Reimbursement — CPAP Not Affected (Direct): INSP’s reimbursement headwinds are specific to hypoglossal nerve stimulation (HNS) CPT codes (64582 and related), not CPAP reimbursement. Hospital and ASC reimbursement rates for INSP procedures “remain unchanged.” CMS has proposed a 12% increase in hospital outpatient reimbursement for the Inspire 5 procedure for 2027. This is a direct positive read-through: CPAP reimbursement is not under pressure, and the broader sleep apnea reimbursement environment is improving.
• GLP-1 Commentary (Direct): INSP management stated that GLP-1 trends “don’t think it really changes our overall demand for Inspire therapy” and characterized GLP-1s as a “long-term benefit to help people lose weight, to get them into the, and to qualify for Inspire therapy.” INSP is seeing “increase in prior authorization” and “capacity returning.” This is a direct positive read-through for RMD: GLP-1s are not cannibalizing sleep apnea device demand; instead, they are expanding the eligible patient pool and improving adherence (consistent with RMD’s own real-world data showing GLP-1 patients have ~11% higher CPAP start rates).
• International Growth (Direct): INSP reported “a very good Q2” internationally, driven by continental Europe (particularly France, which recently received countrywide reimbursement). Growth expected to continue in Germany, Austria, Switzerland, Netherlands, Belgium, UK, Japan, and Singapore. This is a direct positive read-through for RMD’s international device and mask business, confirming that European sleep apnea markets are expanding.
• Project Horizon Restructuring (Indirect): INSP announced a strategic restructuring to generate $30M annualized savings by consolidating supply chain and reallocating resources to patient flow initiatives. This is an indirect read-through: it signals that medical device companies are actively managing cost structures to fund growth, consistent with RMD’s own manufacturing efficiency and logistics optimization programs.
• Competitive Dynamics (Indirect): INSP noted it is aware of “another company approved but still working on preparing for launch” in the HNS market, but does not see a “significant impact at this point.” This is an indirect read-through for RMD: the competitive landscape in sleep apnea devices remains manageable, consistent with RMD’s own commentary that recent competitive device launches have not impacted its market share.

LLY (Eli Lilly) — Q2 2026 Earnings (August 5, 2026)

Read-through type: DIRECT (GLP-1 Demand Strength — Key Tailwind for RMD)

• GLP-1 Demand Strength (Direct): LLY reported adjusted EPS of $8.38 (vs. $6.01 consensus) and raised FY2026 revenue guidance to $85–87B. Mounjaro revenue of $9.9B (+beat) and Zepbound of $4.93B (+beat) both exceeded expectations. LLY also announced a CVS Health partnership enabling GLP-1 access at $29 MinuteClinic visits. This is a direct positive read-through for RMD: continued GLP-1 demand strength validates RMD’s thesis that GLP-1 patients have ~11% higher CPAP start rates and higher resupply rates at 1 and 3 years. Broader GLP-1 adoption expands the pool of patients who are both GLP-1 users and sleep apnea candidates.
• Retatrutide Filing Timeline (Indirect): LLY announced it will file for FDA approval of retatrutide (next-generation triple agonist obesity drug) in Q1 2027. Retatrutide showed 28% average weight loss over 80 weeks in late-stage trials. This is an indirect positive for RMD: higher-efficacy GLP-1s that drive greater weight loss may further increase the proportion of obese patients who are diagnosed with sleep apnea and referred for CPAP therapy.
• CVS/LLY Partnership (Indirect): LLY’s partnership with CVS Health to expand GLP-1 access (transparent pricing, same-day pharmacy pickup, $29 MinuteClinic visits) is an indirect positive for RMD: broader GLP-1 access increases the number of patients on combination GLP-1 + CPAP therapy, which RMD’s data shows drives higher resupply rates.

NVO (Novo Nordisk) — Q2 2026 Earnings (August 4–5, 2026)

Read-through type: INDIRECT (GLP-1 Market Dynamics)

• GLP-1 Market Remains Robust (Indirect): NVO reported Q2 adjusted sales of ~$12.1B (vs. $10.9B consensus) and raised full-year guidance. Wegovy oral version has reached over 5 million prescriptions worldwide since its U.S. launch in January. Despite investor disappointment on the magnitude of the guidance raise, the underlying GLP-1 demand environment remains strong. This is an indirect positive for RMD: the GLP-1 market is not slowing, which supports RMD’s demand generation thesis.
• Ziltivekimab Trial Failure (Neutral): NVO’s heart drug ziltivekimab failed the ZEUS trial. This is neutral for RMD — the failure is in a non-GLP-1 cardiovascular asset and does not affect GLP-1 demand or the sleep apnea market.

GEHC (GE HealthCare) — Q2 2026 Earnings (July 29, 2026)

Read-through type: INDIRECT (Healthcare Utilization, Tariff Refunds)

• Healthcare Utilization Strength (Indirect): GEHC beat Q2 estimates with adjusted EPS of $1.13 (vs. $1.04 consensus) and revenue of $5.30B (vs. $5.26B consensus). Total orders were up 11%, driven by strong commercial execution and new product adoption. CEO Peter Arduini cited “healthy patient volumes, procedural growth, and sustained capital investment by larger health systems.” This is an indirect positive for RMD: a robust healthcare utilization environment supports sleep apnea diagnosis and CPAP prescription rates.
• Tariff Refund Benefit (Indirect): GEHC received $129M in tariff refunds in Q2, which boosted margins. This is an indirect read-through: if RMD has pursued similar tariff refunds, there could be a one-time margin benefit in Q4 FY26. However, RMD has not disclosed a tariff refund program.

9. Insider Transaction Activity

Key Takeaway: The only insider transactions since the Q3 earnings date are routine 10b5-1 planned sales by CEO Mick Farrell, executed monthly under a plan adopted October 31, 2024. These are obligation-driven and carry no discretionary signal. No open-market buys or discretionary sales have been filed. Insider activity is unremarkable.

All CEO transactions are part of a pre-established 10b5-1 trading plan adopted October 31, 2024, involving monthly exercise of stock options at $146.34 and same-day sale of the resulting shares. These are entirely non-discretionary and carry no informational signal about management’s view of the stock. No open-market purchases or discretionary sales have been filed by any insider since the April 30, 2026 earnings date. The absence of discretionary insider buying is unremarkable given the stock’s recovery from its June lows.

Source: SEC Form 4 Filings (Insider Transaction Data); SEC Form 144 Filing (Peter C. Farrell, August 5, 2026).